Blar i forfatter "Tønnessen, Tor Inge"

Viser treff 1-2 av 2

    • Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function 

      Pischke, Søren Erik; Gustavsen, Alice; Orrem, Hilde Lang; Egge, Kjetil Hagene; Courivaud, Frederic A. A.; Fontenelle, Hugues; Despont, Alain; Bongoni, Anjan K.; Rieben, Robert; Tønnessen, Tor Inge; Nunn, Miles A.; Scott, Helge; Skulstad, Helge; Barratt-Due, Andreas; Mollnes, Tom Eirik (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-03-03)
      Inhibition of complement factor 5 (C5) reduced myocardial infarction in animal studies, while no benefit was found in clinical studies. Due to lack of cross-reactivity of clinically used C5 antibodies, different inhibitors were used in animal and clinical studies. Coversin (Ornithodoros moubata complement inhibitor, OmCI) blocks C5 cleavage and binds leukotriene B4 in humans and pigs. We hypothesized ...

    • Endotoxin removal in septic shock with the Alteco LPS Adsorber was safe but showed no benefit compared to placebo in the double-blind randomized controlled trial - the Asset Study 

      Lipcsey, Miklos; Tenhunen, Jyrki; Pischke, Soeren; Kuitunen, Anne; Flaatten, Hans; De Geer, Lina; Sjölin, Jan; Frithiof, Robert; Chew, Michelle S.; Bendel, Stepani; Kawati, Rafael; Larsson, Anders; Mollnes, Tom Eirik; Tønnessen, Tor Inge; Rubertsson, Sten (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-08)
      <i>Purpose</i>: Lipopolysaccharides (LPS) are presumed to contribute to the inflammatory response in sepsis. We investigated if extracorporeal Alteco LPS Adsorber for LPS removal in early gram-negative septic shock was feasible and safe. Also, effects on endotoxin level, inflammatory response, and organ function were assessed.<br><br> <i>Methods</i>: A pilot, double-blinded, randomized, Phase ...